TwinEdge Bioscience has launched!

We are delighted to announce the launch of TwinEdge Bioscience a new cutting-edge biotechnology company, committed to revolutionizing cancer drug development through the application of digital avatars.

Based at the celebrated Biopôle Lausanne in Lausanne, Switzerland, TwinEdge Bioscience has been founded by a complementary team of world-renowned scientists and business veterans (Michael Prosser, Ioannis Xenarios, Kevin Buyens). TwinEdge Bioscience aims to bring large scale, actionable, patient population data to translational and clinical decision points, offering novel and invaluable insight to these key stages of drug development, marking a significant step forward in oncology research.

We invite you to join us for the revolution ahead….! Please follow our progress on LinkedIn at TwinEdge Bioscience, join our mailing list at www.twinedgebio.com, or get in touch directly to see how digital avatars can revolutionise your oncology development programme.